Simcere Pharmaceutical Group Form SC 13D/A December 24, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

Simcere Pharmaceutical Group

(Name of Issuer)

Ordinary Shares, par value US\$0.01 per share

(Title of Class of Securities)

82859P 104(1)

(CUSIP Number)

Yonggang Cao Hony Capital Limited Suite 2701, One Exchange Square Central, Hong Kong +852 3961 9700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 23, 2013

Edgar Filing: Simcere Pharmaceutical Group - Form SC 13D/A

(Date of Event Which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.


Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

 $(1)\ This\ CUSIP\ number\ applies\ to\ the\ Issuer\ \ s\ American\ Depositary\ Shares,\ each\ representing\ two\ Ordinary\ Shares.$






14.

Type of Reporting Person

1. Names of Reporting Persons Hony Capital II GP Ltd. 2. Check the Appropriate Box if a Member of a Group (b) X SEC Use Only 3. 4. Source of Funds OO See Item 3 5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(e) or 2(f) o 6. Citizenship or Place of Organization Cayman Islands 7. Sole Voting Power Number of Shares 8. Shared Voting Power Beneficially Owned by 9. Sole Dispositive Power Each Reporting Person With 10. Shared Dispositive Power 11. Aggregate Amount Beneficially Owned by Each Reporting Person 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares o 13. Percent of Class Represented by Amount in Row (11)



Page 6 of 8 Pages

This Amendment No. 2 amends and supplements the Schedule 13D jointly filed by the Reporting Persons with respect to Simcere Pharmaceutical Group (the Company or the Issweith)the United States Securities and Exchange Commission (the SEC) on March 21, 2013, as amended and restated by Amendment No.1 filed on August 28, 2013 (as so amended and restated, the Original Schedule 13D). Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.

Item 4 Purpose of Transaction

This Amendment amends and supplements Item 4 of the Original Schedule 13D by adding the following immediately prior to the last paragraph of Item 4:

On December 19, 2013, at 10:00 a.m. (Beijing time), an extraordinary general meeting of the shareholders of the Issuer was held at No. 699-18, Xuan Wu Avenue, Xuan Wu District, Nanjing, Jiangsu Province 210042, People s Republic of China. At the extraordinary general meeting, the shareholders of the Issuer voted to approve the Merger Agreement, the plan of merger and the transactions contemplated thereby, including the Merger, and the proposal to adjourn the extraordinary general meeting in order to allow the Issuer to solicit additional proxies in the event that there are insufficient proxies received to pass the special resolution during the extraordinary general meeting.

On December 23, 2013 (New York time), the Issuer and Merger Sub filed a plan of merger with the Cayman Islands Registrar of Companies, which was registered by the Cayman Islands Registrar of Companies as of December 23, 2013, pursuant to which the Merger became effective on December 23, 2013. As a result of the Merger, the Issuer will continue its operations as a wholly owned subsidiary of Parent.

At the effective time of the Merger, the outstanding Ordinary Shares and ADSs immediately prior to the effective time of the Merger ceased to be outstanding and were cancelled, and each Ordinary Share (excluding the Rollover Shares, Ordinary Shares held in the Issuer s treasury and any Ordinary Shares held by a shareholder of the Issuer who is entitled to and properly exercises appraisal rights under the applicable law of the Cayman Islands), including the Ordinary Shares represented by ADSs, was converted into the right to receive cash consideration, without interest, equal to \$4.83 per Ordinary Share (or \$9.66 per ADS).

As a result of the Merger, all of the Ordinary Shares beneficially owned by the Reporting Persons prior to the effective time of the Merger were cancelled, in exchange for the right to subscribe for the ordinary shares of Parent pursuant to the terms of the Merger Agreement and the Contribution Agreement.

As a result of the Merger, the ADSs of the Issuer will no longer be listed on any securities exchange or quotation system, including The New York Stock Exchange, after the filing of Form 25. In addition, 90 days after the filing of Form 15 in connection with the transaction, or such shorter period as may be determined by the Commission, the registration of the ADSs of the Issuer and the Ordinary Shares underlying them and the reporting obligations of the Issuer under the Exchange Act will be terminated.

Edgar Filing: Simcere Pharmaceutical Group - Form SC 13D/A

Item 5	Interest in Securities of the Issuer

This Amendment amends and restates the Item 5 of the Original Schedule 13D in its entirety as set forth below:

(a) (b) As a result of the Merger, all of the Ordinary Shares beneficially owned by the Reporting Persons prior to the effective time were cancelled, in exchange for the right to subscribe for the ordinary shares of Parent pursuant to the terms of the Merger Agreement and the Contribution Agreement.

Edgar Filing: Simcere Pharmaceutical Group - Form SC 13D/A

(c) Except for the transactions described in Item 4, none of the Reporting Persons has effected any transactions in the Ordinary Shares duri past 60 days.	ing the
(d) (e) Not applicable.	

Page 7 of 8 Pages

Page 8 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 24, 2013

Assure Ahead Investments Limited

By: /s/ Shunlong Wang Shunlong Wang

Director

Hony Capital II, L.P.

Acting by its general partner Hony Capital II GP Ltd.

By: /s/ John Huan Zhao

John Huan Zhao

Director

Hony Capital II GP LTD.

By: /s/ John Huan Zhao

John Huan Zhao

Director

Right Lane Limited

By: /s/ Min Ning

Min Ning Director